Learn About Our History

Decades of experience

AVEROA is a biopharmaceutical company bringing innovative solutions to people with renal diseases.

With a patient-centered approach, our mission is to offer patients comprehensive care of their renal diseases, based on effective therapeutic options supported by accurate diagnosis and advanced prognosis tools.

Projects in development are specifically dedicated to proposing alternative treatments for patients suffering from renal diseases but also developing reliable biomarkers or tools to facilitate the diagnosis and assess treatment outcomes to improve the overall management of a patient.    

Parnerships & Collaboration

AVEROA entered into two major agreements


Exclusive Licence

with AKEBIA Therapeutics, Inc. [AKBA], a US-based company that granted AVEROA to develop and commercialize AVA1014 in Europe, UK, Switzerland and Turkey.


Research Collaboration

Research collaboration and license agreement with IDIBELL for the development of a biomarker and a new treatment for renal lithiasis.

Our Team

AVEROA was created in December 2021 by an experienced team with a complementary expertise and a successful track record in the pharmaceutical industry.

Dr Luc-André Granier

President & CEO - Medical Director

Sarah Delbaere

Chief Financial Officer

Caroline Roussel-Maupetit

Chief Operating Officer

Mélanie Cardona

Regulatory Affairs Manager

Scott Donald

Business Development Director

Alexandra Guillermin

Pharmaceutical Development Manager

Catherine Thompson

Clinical-Regulatory Advisor

The values we live by

Provide transformative treatments with a human touch to underserved or overlooked patients with rare or life threatened diseases.


Identify and develop treatments where science can be applied in new ways of treating diseases with high medical needs.


Value-based health care is about putting the patient at the center to produce the best outcomes.


Develop efficient drugs for patients in a smart and quick way.


Science has become a team activity. We recognize its complexity and help innovative drugs reach their next step of development